Journal
NATURE MEDICINE
Volume 22, Issue 5, Pages 547-556Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.4087
Keywords
-
Funding
- US National Institutes of Health (NIH) [K99/R00 HL121177, R21 HL123655, R01 LM05652, R01 GM102365, R24 GM61374, R01 HL123968, R01 HL126527, R01 HL128170, R01 HL130020, R01 AR063963, R01 AG020961, R21 AG04481501, R01 NS089533]
- American Heart Association (AHA) [AHA 14BGIA20480329, AHA 13POST14480004, AHA 13EIA14420025]
- Dixon Translational Research Grant Young Investigator Award
- California Institute of Regenerative Medicine (CIRM) [IT1-06596, TR3-05501, RB5-07469]
- Muscular Dystrophy Association [4320]
- Baxter Foundation
- Burroughs Wellcome Fund Innovation in Regulatory Science Award
Ask authors/readers for more resources
Doxorubicin is an anthracycline chemotherapy agent effective in treating a wide range of malignancies, but it causes a dose-related cardiotoxicity that can lead to heart failure in a subset of patients. At present, it is not possible to predict which patients will be affected by doxorubicin-induced cardiotoxicity (DIC). Here we demonstrate that patient-specific human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) can recapitulate the predilection to DIC of individual patients at the cellular level. hiPSC-CMs derived from individuals with breast cancer who experienced DIC were consistently more sensitive to doxorubicin toxicity than hiPSC-CMs from patients who did not experience DIC, with decreased cell viability, impaired mitochondria! and metabolic function, impaired calcium handling, decreased antioxidant pathway activity, and increased reactive oxygen species production. Taken together, our data indicate that hiPSC-CMs are a suitable platform to identify and characterize the genetic basis and molecular mechanisms of DIC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available